1-3 of 3
William Plunkett, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma

William G. Wierda, MD, R. Chen, MD, William Plunkett, MD, Steven Coutre, MD, Ashraf Z. Badros, MD, Leslie Popplewell, MD, David Siegel, MD, Rajni Sinha, MD, Donald Harvey, Pharm.D., Judith Fox, PhD, Kristi Mahadocon, Peggy Kegley, Mary G. Bolton, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 3178.
https://doi.org/10.1182/blood.V112.11.3178.3178
Published: 2008
Journal Articles

A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML).

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, William Wierda, MD, Alessandra Ferrajoli, MD, Rong Chen, MD, Farhad Ravandi, MD, William Plunkett, MD, Jorge Cortes, MD
Journal: Blood
Blood (2006) 108 (11): 2174.
https://doi.org/10.1182/blood.V108.11.2174.2174
Published: 2006
Journal Articles

Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.

Elias Jabbour, MD, Hagop Kantarjian, MD, Miloslav Beran, MD, PhD, DVM, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Sherry Pierce, RN, BSN, BA, Jianqin Shan, PhD, William Plunkett, MD, PhD, Michael Keating, MD, Elihu Estey, MD
Journal: Blood
Blood (2005) 106 (11): 2529.
https://doi.org/10.1182/blood.V106.11.2529.2529
Published: 2005